Teladoc (NYSE:TDOC) CEO Jason N. Gorevic sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $41.36, for a total value of $1,034,000.00. Following the transaction, the chief executive officer now directly owns 661,184 shares in the company, valued at $27,346,570.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Teladoc stock opened at $42.65 on Thursday. Teladoc has a 12-month low of $22.73 and a 12-month high of $44.65. The firm has a market cap of $2,623.37, a P/E ratio of -25.85 and a beta of 0.36. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.37.
Teladoc (NYSE:TDOC) last announced its quarterly earnings results on Tuesday, February 27th. The health services provider reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.10). Teladoc had a negative return on equity of 20.95% and a negative net margin of 45.77%. The company had revenue of $77.14 million for the quarter, compared to the consensus estimate of $76.14 million. equities analysts anticipate that Teladoc will post -1.37 EPS for the current year.
A number of equities analysts have recently weighed in on TDOC shares. Canaccord Genuity upped their target price on Teladoc from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Chardan Capital reaffirmed a “buy” rating and set a $47.00 target price (down from $48.00) on shares of Teladoc in a research report on Wednesday, February 28th. KeyCorp reaffirmed an “overweight” rating and set a $50.00 target price (up from $41.00) on shares of Teladoc in a research report on Thursday, March 15th. ValuEngine raised Teladoc from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $35.00 target price (up from $31.00) on shares of Teladoc in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. Teladoc has a consensus rating of “Buy” and an average price target of $41.67.
Large investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in Teladoc in the 4th quarter valued at $101,000. Montag A & Associates Inc. bought a new position in Teladoc in the 4th quarter valued at $200,000. Xact Kapitalforvaltning AB bought a new position in Teladoc in the 4th quarter valued at $203,000. Buckley Wealth Management LLC bought a new position in Teladoc in the 4th quarter valued at $221,000. Finally, Guggenheim Capital LLC bought a new position in Teladoc in the 4th quarter valued at $272,000.
COPYRIGHT VIOLATION WARNING: This piece was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/04/19/teladoc-tdoc-ceo-jason-n-gorevic-sells-25000-shares-of-stock.html.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.